Publication | Open Access

Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials

VaccinationVaccine SafetyVaccinologyPhase-2 Clinical TrialsVaccine DevelopmentVaccine TargetOptimum FormulationImmunologyVaccine TestingVaccine EfficacyMedicineCovid-19